Announced details
Companion animals, particularly inflammatory diseases, joint diseases, gait disorders and other age-related conditions in dogs. Collection of foundational data toward out-licensing overseas.
No matters apply with respect to personnel relationships, business relationships or status as a related party. ADRセラピューティクス has already entered into a joint research agreement.
3-7-27 Shimorenjaku, Mitaka, Tokyo; Representative Director: Ito Hiroshi (伊藤 博). Development, manufacture and sale of pharmaceuticals and quasi-drugs for human and animal use, in vitro diagnostic pharmaceuticals, and medical equipment. Established on 16 February 2021. Operating results and financial position are undisclosed.
The impact of commencing this joint research on the Company's financial results is currently expected to be minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Neocella (ネオセラ) |
| Counterparty | 株式会社メディカル・アーク |
| Counterparty overview | 3-7-27 Shimorenjaku, Mitaka, Tokyo; Representative Director: Ito Hiroshi (伊藤 博). Development, manufacture and sale of pharmaceuticals and quasi-drugs for human and animal use, in vitro diagnostic pharmaceuticals, and medical equipment. Established on 16 February 2021. Operating results and financial position are undisclosed. |
| Relationship with the Company | No matters apply with respect to personnel relationships, business relationships or status as a related party. ADRセラピューティクス has already entered into a joint research agreement. |
| Launch date | 21 May 2026 (the commencement date of the joint research; actual) |
| Applicable area | Companion animals, particularly inflammatory diseases, joint diseases, gait disorders and other age-related conditions in dogs. Collection of foundational data toward out-licensing overseas. |
| Impact on Business Performance | The impact of commencing this joint research on the Company's financial results is currently expected to be minor. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To explore the potential application of Neocella to the treatment of diseases in dogs and accumulate case results and post-treatment follow-up data with a view to the early practical application of Neocella.